Milliman DNA benefits
Develop strategic products
Create informed offerings and policies based on populated data and research.
Educate customers
Help customers learn about gene and cell therapies and their potential treatment-eligible members.
Reduce risk
Improve underwriting processes and guidelines with the most comprehensive information available.
Stay up-to-date
Acquire the latest information on approvals and changes in the gene and cell therapy market.
Streamline scenario testing
Focus on deep dives related to sources of uncertainty and key assumptions.
Contract effectively
Identify the conditions with the highest potential impact to prioritize for cost or reimbursement mitigation tactics.
Milliman DNA features
Customized population
Specify the plan year and age distribution to establish baseline assumptions for a commercial, Medicare or Medicaid group.
Transparent results
Export simulations of the scenarios for additional modeling of benefit design features or risk mitigation techniques.
Timely updates
Receive updates on FDA approval status, price announcements, and new therapies appearing on the FDA review horizon.
Research Repository
Familiarize yourself with the indicated conditions and associated patient population for all single-administration gene and cell therapies in the upcoming 18-month window.
Compelling visuals
Access multiple output views to explore annual expected cases or costs.
Dynamic inputs
Override baseline assumptions for prevalence, coverage, or demand to create scenarios that can be saved and retrieved.